A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

The main purpose of this study is to evaluate the safety of HY-2003 in subjects with moderate to severe submental fat accumulation at different doses and dosing frequencies in comparison with the positive control and placebo. The secondary objectives include: Evaluating the pharmacokinetic characteristics of HY-2003 after a single administration in humans and obtaining preliminary pharmacokinetic parameters; Evaluating the efficacy of HY-2003 under different doses and dosing frequencies, compared with the positive control and placebo, in the treatment of subjects with moderate to severe submen

Trial Details

NCT ID
NCT06756490
Phase
PHASE1
Sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • HY-2003 (10 mg/ml), BELKYRA and placebo
  • HY-2003 (5 mg/ml) and placebo
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Fully understand the requirements of the trial, and signed the informed consent form voluntarily;
  • The subjects should have good compliance, are able to fully understand this clinical trial, have reasonable expectations for the injection effects,…
  • Aged 18 to 65 years (including boundary values), male or female.
  • At screening and baseline, the investigator rated moderate to severe submental outline protrusion due to submental fat accumulation according to th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →